Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CHE Stock Forecast 2025-2026
$421.97
Current Price
$6.15B
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CHE Price Targets
+41.0%
To High Target of $595.00
+36.5%
To Median Target of $576.00
+30.3%
To Low Target of $550.00
CHE Price Momentum
-3.9%
1 Week Change
-2.0%
1 Month Change
-23.6%
1 Year Change
-20.4%
Year-to-Date Change
-32.3%
From 52W High of $623.61
+3.3%
From 52W Low of $408.42
📊 TOP ANALYST CALLS
Did CHE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Chemed is one of their latest high-conviction picks.
Latest CHE Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, CHE has a bullish consensus with a median price target of $576.00 (ranging from $550.00 to $595.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $421.97, the median forecast implies a 36.5% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joanna Gajuk at B of A Securities, projecting a 41.0% upside. Conversely, the most conservative target is provided by Brian Tanquilut at Jefferies, suggesting a 30.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CHE Analyst Ratings
4
Buy
0
Hold
0
Sell
CHE Price Target Range
Low
$550.00
Average
$576.00
High
$595.00
Current: $421.97
Latest CHE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CHE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 10, 2025 | RBC Capital | Ben Hendrix | Outperform | Maintains | $572.00 |
| Sep 10, 2025 | B of A Securities | Joanna Gajuk | Buy | Maintains | $595.00 |
| Sep 2, 2025 | Jefferies | Brian Tanquilut | Buy | Upgrade | $550.00 |
| Jul 31, 2025 | Oppenheimer | Michael Wiederhorn | Outperform | Maintains | $580.00 |
| Jul 31, 2025 | RBC Capital | Ben Hendrix | Outperform | Maintains | $589.00 |
| Jul 25, 2025 | Jefferies | Brian Tanquilut | Hold | Initiates | $500.00 |
| Jun 30, 2025 | RBC Capital | Ben Hendrix | Outperform | Maintains | $640.00 |
| Jun 30, 2025 | B of A Securities | Joanna Gajuk | Buy | Maintains | $650.00 |
| Apr 28, 2025 | RBC Capital | Ben Hendrix | Outperform | Maintains | $674.00 |
| Mar 14, 2025 | RBC Capital | Ben Hendrix | Outperform | Maintains | $667.00 |
| Nov 5, 2024 | RBC Capital | Ben Hendrix | Outperform | Maintains | $633.00 |
| May 21, 2024 | RBC Capital | Ben Hendrix | Outperform | Maintains | $697.00 |
| Mar 4, 2024 | RBC Capital | Ben Hendrix | Outperform | Maintains | $712.00 |
| Feb 29, 2024 | Oppenheimer | Michael Wiederhorn | Outperform | Maintains | $650.00 |
| Jan 17, 2024 | Oppenheimer | Michael Wiederhorn | Outperform | Maintains | $625.00 |
| Oct 30, 2023 | RBC Capital | Ben Hendrix | Outperform | Maintains | $604.00 |
| Jul 31, 2023 | RBC Capital | Ben Hendrix | Outperform | Maintains | $576.00 |
| Jul 27, 2023 | Oppenheimer | Michael Wiederhorn | Outperform | Maintains | $590.00 |
| May 1, 2023 | RBC Capital | Ben Hendrix | Outperform | Maintains | $610.00 |
| Apr 28, 2023 | Oppenheimer | Michael Wiederhorn | Outperform | Maintains | $610.00 |
Chemed Corporation (CHE) Competitors
The following stocks are similar to Chemed based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Chemed Corporation (CHE) Financial Data
Chemed Corporation has a market capitalization of $6.15B with a P/E ratio of 22.4x. The company generates $2.53B in trailing twelve-month revenue with a 11.0% profit margin.
Revenue growth is +3.1% quarter-over-quarter, while maintaining an operating margin of +12.0% and return on equity of +24.1%.
Valuation Metrics
Market Cap
$6.15B
Enterprise Value
$5.97B
P/E Ratio
22.4x
PEG Ratio
-1.9x
Price/Sales
2.4x
Growth & Margins
Revenue Growth (YoY)
+3.1%
Gross Margin
+31.5%
Operating Margin
+12.0%
Net Margin
+11.0%
EPS Growth
-15.2%
Financial Health
Cash/Price Ratio
+2.2%
Current Ratio
1.4x
Debt/Equity
13.1x
ROE
+24.1%
ROA
+13.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Chemed Corporation (CHE) Business Model
About Chemed Corporation
What They Do
Provides hospice care and plumbing services.
Business Model
Chemed Corporation operates through two main segments: VITAS Healthcare, which provides hospice care, and Roto-Rooter, which offers plumbing and drain cleaning services. The company generates revenue by delivering essential healthcare services to terminally ill patients and maintaining residential and commercial properties, ensuring a steady income stream in both sectors.
Additional Information
As one of the largest hospice care providers in the U.S., VITAS Healthcare significantly influences the healthcare sector, while Roto-Rooter's plumbing services contribute to its stability. This strategic diversification allows Chemed to maintain resilience in various economic conditions and positions it for sustained growth.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
15,695
CEO
Mr. Kevin J. McNamara
Country
United States
IPO Year
1973
Website
www.chemed.comChemed Corporation (CHE) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Chemed (CHE) Down 5.2% Since Last Earnings Report: Can It Rebound?
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nov 27, 2025
By Zacks Equity Research
Realtime BLOG
Latest News
Quick Summary
Chemed Corporation (CHE) will present at the UBS Global Healthcare Conference on November 11, 2025, at 2:00 PM EST, featuring key executives including the CFO and CEO.
Why It Matters
Chemed Corporation's participation in the UBS Global Healthcare Conference signals potential insights into its strategy and performance, impacting investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Wall Street Analysts Predict a 32.69% Upside in Chemed (CHE): Here's What You Should Know
25 days ago
Quick Summary
Analysts' price targets for Chemed (CHE) suggest a 32.7% upside. Consensus on rising earnings estimates indicates potential stock growth.
Why It Matters
Analysts' price targets suggest significant upside for Chemed (CHE), indicating potential growth. Consensus on earnings estimates reinforces positive sentiment, impacting investor confidence.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Chemtrade Logistics Income Fund will hold its Q3 2025 earnings call on November 12, 2025, at 10:00 AM EST, featuring CFO Rohit Bhardwaj and CEO Scott Rook.
Why It Matters
The earnings call provides insights into Chemtrade Logistics' financial performance and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Chemed Corporation (NYSE:CHE) has declared a quarterly cash dividend of $0.60 per share, payable on December 5, 2025, to shareholders of record as of November 17, 2025.
Why It Matters
Chemed's consistent dividend payment highlights financial stability and commitment to returning capital to shareholders, which can enhance investor confidence and attract income-focused buyers.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Chemed Corporation (NYSE: CHE) will present at the UBS 2025 Global Healthcare Conference on November 11, 2025, at 2:00 p.m. ET in Palm Beach Gardens, Florida.
Why It Matters
Chemed Corporation's presentation at a major healthcare conference may provide insights into its strategic direction, financial health, and growth prospects, influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Schwartz Investment Counsel sold 28,771 shares of Chemed Corporation for about $13.03 million. Post-sale, they hold 111,033 shares valued at $49.71 million, representing 1.67% of AUM.
Why It Matters
Schwartz Investment Counsel's reduction in Chemed shares may signal a shift in their investment strategy, potentially affecting Chemed's stock performance and investor sentiment.
Source: The Motley Fool
Market Sentiment:
Neutral
Frequently Asked Questions About CHE Stock
What is Chemed Corporation's (CHE) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, Chemed Corporation (CHE) has a median price target of $576.00. The highest price target is $595.00 and the lowest is $550.00.
Is CHE stock a good investment in 2026?
According to current analyst ratings, CHE has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $421.97. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CHE stock?
Wall Street analysts predict CHE stock could reach $576.00 in the next 12 months. This represents a 36.5% increase from the current price of $421.97. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Chemed Corporation's business model?
Chemed Corporation operates through two main segments: VITAS Healthcare, which provides hospice care, and Roto-Rooter, which offers plumbing and drain cleaning services. The company generates revenue by delivering essential healthcare services to terminally ill patients and maintaining residential and commercial properties, ensuring a steady income stream in both sectors.
What is the highest forecasted price for CHE Chemed Corporation?
The highest price target for CHE is $595.00 from Joanna Gajuk at B of A Securities, which represents a 41.0% increase from the current price of $421.97.
What is the lowest forecasted price for CHE Chemed Corporation?
The lowest price target for CHE is $550.00 from Brian Tanquilut at Jefferies, which represents a 30.3% increase from the current price of $421.97.
What is the overall CHE consensus from analysts for Chemed Corporation?
The overall analyst consensus for CHE is bullish. Out of 6 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $576.00.
How accurate are CHE stock price projections?
Stock price projections, including those for Chemed Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 6, 2025 6:57 PM UTC